The University of Southampton
University of Southampton Institutional Repository

The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom

The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom
The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom
68Ga-DOTATATE PET/CT scanning is a widely accepted method for imaging of neuroendocrine tumors. This cross-sectional study was performed to review the first 8 y of patient data from a large 68Ga-DOTATATE PET/CT database in order to establish the impact of the modality on patient treatment and survival. Methods: Demographic data, clinical outcome, survival, and change in management after 68Ga-DOTATATE PET/CT were evaluated. Results: Between May 2005 and August 2013, 1,258 68Ga-DOTATATE PET/CT scans were obtained in 728 patients with confirmed or suspected neuroendocrine tumors. In most patients, the primary site was located in the midgut (26.4%). Analysis of NET grading in patients with known histopathologic data revealed that 35.7% had NET grade G1, 12.2% G2, and 8.7% G3. The most common indications for 68Ga-DOTATATE PET/CT were follow-up (24.4%) and initial tumor staging (23.4%). Of the 1,258 68Ga-DOTATATE PET/CT scans completed, 75.7% were positive and 24.3% negative; there were 14 false-positive and 29 false-negative scans. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 97%, 95.1%, 96.6%, 98.5%, and 90.4%, respectively. In 40.9% of patients, the treatment plan was changed after the scans, owing mainly to new, unexpected findings. Statistically significant differences in survival were shown between patients with G1, G2, and G3 grade tumors (P , 0.0001) and also between patients with bone metastasis versus patients with soft-tissue metastasis (P , 0.0001). Conclusion: 68Ga-DOTATATE PET/CT scanning is safe and influences management in a large proportion of patients. Prognosis was dependent on tumor grade, and the presence of bone metastasis was associated with worse overall survival.
68Ga-DOTATATE, Neuroendocrine tumors, PET/CT, Somatostatin receptor imaging
0161-5505
34-40
Skoura, Evangelia
74909001-1531-4c9c-8c5a-e03a939323c4
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Mohmaduvesh, Mullan
fc435e5a-ec0b-48df-a0dd-5c602f6ffb3a
Panagiotidis, Emmanouil
bec78c6c-2b2a-4694-a002-7a92b0e62d3d
Al Harbi, Mohammed
c2cfaa91-65d2-4d2a-8274-3a1cdf58cb22
Toumpanakis, Christos
c0d3cb17-4ca4-44ee-a8b4-5383e38001f7
Almukhailed, Omar
47298948-bece-44c1-a2bd-1088a1bc810a
Kayani, Irfan
2dd8714b-188c-49d7-8881-12f8ac201839
Syed, Rizwan
7f06388f-ed3b-47c4-92b6-48c74a414c81
Navalkissoor, Shaunak
3098cb46-1633-4bc4-a5d6-b48f9c7c2463
Ell, Peter J.
63a722f6-84a2-4396-a849-1bc0a667e53f
Caplin, Martyn E.
b00b4bdb-ebb1-45d9-9cd7-054c00ad2d4c
Bomanji, Jamshed
fee906a9-b97b-4141-bdee-1d9c70062af7
Skoura, Evangelia
74909001-1531-4c9c-8c5a-e03a939323c4
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Mohmaduvesh, Mullan
fc435e5a-ec0b-48df-a0dd-5c602f6ffb3a
Panagiotidis, Emmanouil
bec78c6c-2b2a-4694-a002-7a92b0e62d3d
Al Harbi, Mohammed
c2cfaa91-65d2-4d2a-8274-3a1cdf58cb22
Toumpanakis, Christos
c0d3cb17-4ca4-44ee-a8b4-5383e38001f7
Almukhailed, Omar
47298948-bece-44c1-a2bd-1088a1bc810a
Kayani, Irfan
2dd8714b-188c-49d7-8881-12f8ac201839
Syed, Rizwan
7f06388f-ed3b-47c4-92b6-48c74a414c81
Navalkissoor, Shaunak
3098cb46-1633-4bc4-a5d6-b48f9c7c2463
Ell, Peter J.
63a722f6-84a2-4396-a849-1bc0a667e53f
Caplin, Martyn E.
b00b4bdb-ebb1-45d9-9cd7-054c00ad2d4c
Bomanji, Jamshed
fee906a9-b97b-4141-bdee-1d9c70062af7

Skoura, Evangelia, Michopoulou, Sofia, Mohmaduvesh, Mullan, Panagiotidis, Emmanouil, Al Harbi, Mohammed, Toumpanakis, Christos, Almukhailed, Omar, Kayani, Irfan, Syed, Rizwan, Navalkissoor, Shaunak, Ell, Peter J., Caplin, Martyn E. and Bomanji, Jamshed (2016) The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. Journal of Nuclear Medicine, 57 (1), 34-40. (doi:10.2967/jnumed.115.166017).

Record type: Article

Abstract

68Ga-DOTATATE PET/CT scanning is a widely accepted method for imaging of neuroendocrine tumors. This cross-sectional study was performed to review the first 8 y of patient data from a large 68Ga-DOTATATE PET/CT database in order to establish the impact of the modality on patient treatment and survival. Methods: Demographic data, clinical outcome, survival, and change in management after 68Ga-DOTATATE PET/CT were evaluated. Results: Between May 2005 and August 2013, 1,258 68Ga-DOTATATE PET/CT scans were obtained in 728 patients with confirmed or suspected neuroendocrine tumors. In most patients, the primary site was located in the midgut (26.4%). Analysis of NET grading in patients with known histopathologic data revealed that 35.7% had NET grade G1, 12.2% G2, and 8.7% G3. The most common indications for 68Ga-DOTATATE PET/CT were follow-up (24.4%) and initial tumor staging (23.4%). Of the 1,258 68Ga-DOTATATE PET/CT scans completed, 75.7% were positive and 24.3% negative; there were 14 false-positive and 29 false-negative scans. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 97%, 95.1%, 96.6%, 98.5%, and 90.4%, respectively. In 40.9% of patients, the treatment plan was changed after the scans, owing mainly to new, unexpected findings. Statistically significant differences in survival were shown between patients with G1, G2, and G3 grade tumors (P , 0.0001) and also between patients with bone metastasis versus patients with soft-tissue metastasis (P , 0.0001). Conclusion: 68Ga-DOTATATE PET/CT scanning is safe and influences management in a large proportion of patients. Prognosis was dependent on tumor grade, and the presence of bone metastasis was associated with worse overall survival.

This record has no associated files available for download.

More information

Accepted/In Press date: 5 October 2015
e-pub ahead of print date: 4 January 2016
Keywords: 68Ga-DOTATATE, Neuroendocrine tumors, PET/CT, Somatostatin receptor imaging

Identifiers

Local EPrints ID: 487900
URI: http://eprints.soton.ac.uk/id/eprint/487900
ISSN: 0161-5505
PURE UUID: eed69347-7f9c-451c-9cbd-0f8f86fce373

Catalogue record

Date deposited: 08 Mar 2024 17:59
Last modified: 17 Mar 2024 07:57

Export record

Altmetrics

Contributors

Author: Evangelia Skoura
Author: Sofia Michopoulou
Author: Mullan Mohmaduvesh
Author: Emmanouil Panagiotidis
Author: Mohammed Al Harbi
Author: Christos Toumpanakis
Author: Omar Almukhailed
Author: Irfan Kayani
Author: Rizwan Syed
Author: Shaunak Navalkissoor
Author: Peter J. Ell
Author: Martyn E. Caplin
Author: Jamshed Bomanji

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×